论文部分内容阅读
目的评价新辅助化疗在妇科恶性肿瘤治疗中的有效性。方法以紫杉醇联合顺铂或卡铂术前对28例局部晚期宫颈癌及16例晚期大量腹水的卵巢癌患者行1~2疗程的新辅助化疗,评价其有效性。结果 28例宫颈癌患者中,完全缓解(CR)4例,部分缓解(PR)18例,临床总有效率78.6%;16例卵巢癌患者化疗后腹水明显减少。结论术前新辅助化疗对局部晚期宫颈癌治疗安全有效,对于合并大量腹水的卵巢癌患者可以减少或消退腹水,创造手术机会。
Objective To evaluate the effectiveness of neoadjuvant chemotherapy in the treatment of gynecologic malignancies. Methods A total of 28 patients with locally advanced cervical cancer and 16 patients with advanced ascites who had advanced ovarian cancer were treated with paclitaxel plus cisplatin or carboplatin for 1 ~ 2 courses of neoadjuvant chemotherapy before operation. The efficacy was evaluated. Results Among the 28 patients with cervical cancer, 4 were completely relieved (CR), 18 were partly relieved (PR), and the total clinical effective rate was 78.6%. Ascites was significantly decreased in 16 patients with ovarian cancer after chemotherapy. Conclusion Preoperative neoadjuvant chemotherapy is safe and effective for the treatment of locally advanced cervical cancer. The treatment of ovarian cancer patients with large amount of ascites can reduce or eliminate ascites and create surgical opportunities.